type 4 cyclic nucleotide phosphodiesterase inhibitors pipeline insight

DelveInsight’s, “Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors - Pipeline Insight, 2025,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Understanding

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Overview

Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolytic destruction of the intracellular second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), to produce 5’-AMP and 5’-GMP, respectively. Type 4 cyclic nucleotide phosphodiesterases (PDE4) are a family of low km 3',5'-cyclic adenosine monophosphate (cAMP)-specific phosphodiesterases including at least 20 isozymes encoded by four genes (PDE4A, PDE4B, PDE4C, and PDE4D) in mammals. Because PDE4 isoforms exhibit widespread tissue distribution, perhaps more than any other PDE family, inhibition of PDE4 enzymes alters cAMP-signaling in many cells. The development of PDE4 inhibitors with improved therapeutic indexes has been a major focus of pharmaceutical research for the treatment of chronic inflammatory diseases.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors R&D. The therapies under development are focused on novel approaches for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors.

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Emerging Drugs Chapters

This segment of the Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Emerging Drugs

 

Ensifentrine : Verona Pharma

Ensifentrine is an inhaled, first-in-class dual inhibitor of phosphodiesterase 3 (PDE3) and 4 (PDE4). The drug is in Phase III clinical studies for the treatment of chronic obstructive pulmonary disease and in Phase II developmental studies for asthma and cystic fibrosis treatment. In April 2021, Verona Pharma has reported positive data from a pilot study evaluating a pressurised metered-dose inhaler (pMDI) formulation of ensifentrine to treat Covid-19.

 

Difamilast: Otsuka Pharmaceutical

Difamilast is an investigational non-steroidal topical anti-inflammatory PDE4 inhibitor. The drug is in development for the treatment of mild to moderate atopic dermatitis. Medimetriks has sole exclusive U.S rights to develop and commercialize MM36 (difamilast). In September 2020, Otsuka Pharmaceutical announced that an application has been submitted to the Pharmaceuticals and Medical Devices Agency in Japan to seek manufacturing and marketing approval for difamilast (OPA-15406) in patients with atopic dermatitis.

Further product details are provided in the report……..

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors

There are approx. 20+ key companies which are developing the Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors. The companies which have their Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, Otsuka Pharmaceutical.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

 

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs.

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Report Insights

• Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs?
• How many Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?